Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06207409 · ClinicalTrials.gov registry record · NA
Program for Alleviating and Reducing Trauma, Stress, and Substance Use
A NA study, sponsored by Cambridge Health Alliance.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT06207409: Completed NA study, sponsored by Cambridge Health Alliance.
NCT06207409 is a NA study that has completed, run by Cambridge Health Alliance. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06207409, a NA study, has completed, sponsored by Cambridge Health Alliance.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
This single-arm study will test the preliminary efficacy of a virtually delivered, live-online 12-week group model of Internal Family Systems (IFS) for individuals with posttraumatic stress disorder (PTSD) and substance use disorders (Program for Alleviating and Reducing Trauma, Stress, and Substance Use, PARTS-SUD). Participants will be in a group for 12 weeks and will be asked to complete survey sessions at baseline and during week 4, 8 and 12.
Primary Outcome
The primary aim of this study is to examine the feasibility of a live-online version of the PARTS program defined as 70% of participants completing at least 75% (9/12) of groups.
Interventions
- BEHAVIORAL PARTS-SUD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2025-03-30 |
| Phase | NA |
What the finished NCT06207409 record still lists
NCT06207409 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which PARTS-SUD is the first listed.
NCT06207409 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06207409 about?
NCT06207409 is a clinical study titled "Program for Alleviating and Reducing Trauma, Stress, and Substance Use". This single-arm study will test the preliminary efficacy of a virtually delivered, live-online 12-week group model of Internal Family Systems (IFS) for individuals with posttraumatic stress disorder (PTSD) and substance use disorders (Program for Alleviating and Reducing Trauma, Stress, and Substanc...
What is the current status of trial NCT06207409?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2023-09-01. Estimated completion is 2025-03-30.
What interventions are being tested in trial NCT06207409?
The interventions under investigation include: PARTS-SUD (BEHAVIORAL).
Who is sponsoring clinical trial NCT06207409?
This trial is sponsored by Cambridge Health Alliance, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06207409's enrollment target sits among peer trials
19 1861st of 2000 higher than 138 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI